

Soft Tissue Sarcoma (STS) -Market Insights, Epidemiology and Market Forecast – 2027

STS makes up 1% to 2% of all cancer types and have been estimated annual Incidence of 30 cases among every one million people. Routinely-tabulated STS rates do not include the organ-specific sarcomas and thus underestimate true STS rates.



Albany, Jan 31, 2019 (Issuewire.com) - [Soft Tissue Sarcoma \(STS\) -Market Insights, Epidemiology and Market Forecast – 2027](#)

STS makes up 1% to 2% of all cancer types and has been estimated annual Incidence of 30 cases among every one million people. Routinely-tabulated STS rates do not include the organ-specific sarcomas and thus underestimate true STS rates

- These tumours develop mainly in adults around the age of 50, the frequency increases with age; and 10% of patients are children and adolescents. The incidence of Leiomyosarcomas mirrors with advancing age; synovial sarcomas are more common in young adults, and rhabdomyosarcomas predominate in early childhood
- The highest Incidence is seen in the over 85-year-old age group, particularly males, where the Incidence reaches 230 per million per year and exceeds the rate for females of that age by a ratio of 1.9:1
- In the US, estimates of STS for the current year are found to be about 13,040 new cases diagnosed (7,370 cases in males and 5,670 cases in females) and 5,150 Americans (2,770 males and 2,380 females) are expected to die of soft tissue sarcomas
- In the UK between 1996 and 2010, 43,590 patients were diagnosed and incidence rates have increased gradually, but significantly, from 39 per million in 1996 to 45 per million in 2010.

(Albany, US) DelveInsight launched a new report on [Soft Tissue Sarcoma \(STS\) -Market Insights, Epidemiology and Market Forecast – 2027](#)

[Request for sample pages](#)

[Key topics covered](#)

- The report provides an in-depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends.

- The report provides insights about the historical and current patient pool and forecasted trend for 7 major markets.
- The report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs.
- The market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
- This report focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2027.

“Soft-tissue Sarcomas are broadly categorized into: “Adipocytic; Fibroblastic/Myofibroblastic; Fibrohistiocytic; Smooth Muscle; Pericytic; Skeletal Muscle; Vascular; Chondro-Osseous; Gastrointestinal Stromal; Nerve Sheath; Tumors of uncertain Differentiation; Undifferentiated/Unclassified Sarcomas.”

In the case of STS, despite lower incidence rates, the years of life lost can often be substantial. The market outlook and treatment landscape of STS have changed dramatically in the last decades, with advances in the diagnosis of subtyping and with the introduction of targeted therapies. The treatment market is segmented into surgery, radiation therapy, chemotherapy, anti-angiogenesis drugs and targeted therapy.

After the appropriate biopsy and diagnosis, the Surgery is done with the removal of the tumour and some surrounding healthy tissues. The high grade and larger than 2 inches (5 cm) are often treated with a combination of surgery and radiation therapy or chemotherapy, to shrink the tumour and make removal easier.

Companies covered

- **Nanobiotix**
- **Blueprint Medicines**
- **TRACON Pharmaceuticals**
- **Bayer**
- **Medinol**

And many others

Drugs covered

- **Avapritinib**
- **AL3818**
- **NBTXR3**
- **TRC105**

And many others

[Table of contents](#)

1 Report Introduction

1.1 Soft Tissue Sarcoma Market Overview at a Glance

2.1. Market Share Distribution of Soft Tissue Sarcoma in 2017

2.2. Market Share Distribution of Soft Tissue Sarcoma in 2027

- **Disease Background and Overview: Soft Tissue Sarcoma**

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

- **Epidemiology and Patient Population**

4.1. Key Findings

- **Epidemiology of Soft Tissue Sarcoma by Countries**

5.1. United States

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.5. France

5.6. Italy

5.7. Spain

5.8. United Kingdom

5.9. Japan

- **Current Treatment & Medical practices**
- **Unmet Needs of the Soft Tissue Sarcoma**
- **Marketed Therapies**

8.1. Drug A: Company 1

8.2. Drug B: Company 2

- **Pipeline Therapies – At a glance**
- **Key Cross Competition**
- **Emerging Therapies for Soft Tissue Sarcoma**

11.1. Drug C: Company 3

11.2. Drug D: Company 4

- **Soft Tissue Sarcoma: 7MM Market Analysis**
- **Soft Tissue Sarcoma: Country-Wise Market Analysis**

13.1. United States

13.2. EU-5

13.3. Japan

14. Market Drivers

14.1 Market Barriers

15. Appendix

16 Report Methodology

17.1. Sources

17.2 DelveInsight Capabilities

18. Disclaimer

About [DelveInsight](#)

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:

Shruti Thakur

info@delveinsight.com

+919650213330

Media Contact

Delveinsight Business Reserarch LLP

info@delveinsight.com

9193216187

304 S. Jones Blvd #2432, Las Vegas NV 89107

Source : DelveInsight

See on IssueWire : <https://www.issuewire.com/soft-tissue-sarcoma-sts-market-insights-epidemiology-and-market-forecast-2027-1623988756537430>